An efficient therapeutic approach to patients with acute promyelocytic leukemia using a combination of arsenic trioxide with low-dose all-trans retinoic acid

Hematological Oncology

Volumn 22, Issue 2, 2004, Pages 63-71

  Wang, Guanjun ^a   Li, Wei ^a   Cui, Jiuwei ^a   Gao, Sujun ^a   Yao, Cheng ^a   Jiang, Zhenyu ^a   Song, Yanqiu ^a   Yuan, Chang Ji ^a   Yang, Yan ^a   Liu, Ziling ^a   Cai, Lu ^a,b  

^a JILIN UNIVERSITY   (China)

^b University of Louisville School of Medicine   (United States)

Author keywords

Acute promyelocytic leukemia; All trans retinoic acid; Arsenic; Combined therapy

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ARSENIC TRIOXIDE; ASPARTATE AMINOTRANSFERASE; CYTARABINE; DAUNORUBICIN; FIBRIN DEGRADATION PRODUCT; FIBRINOGEN; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA;

ADOLESCENT; ADULT; ANOREXIA; ATRIOVENTRICULAR BLOCK; BLEEDING; BONE PAIN; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG FEVER; DYSPNEA; EDEMA; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART LEFT BUNDLE BRANCH BLOCK; HUMAN; LEUKEMIA REMISSION; LIVER TOXICITY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NAUSEA; PARTIAL THROMBOPLASTIN TIME; PERITONEUM EXUDATE; PLEURA EFFUSION; PR INTERVAL; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTHROMBIN TIME; REVIEW; SINUS TACHYCARDIA; SKIN TOXICITY; SKIN ULCER; ST SEGMENT DEPRESSION; THROMBOCYTE COUNT; TREATMENT OUTCOME; VOMITING; VULVA DISEASE;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARSENICALS; FEMALE; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; OXIDES; RECURRENCE; REMISSION INDUCTION; TREATMENT OUTCOME; TRETINOIN;

EID: 6944247414     PISSN: 02780232     EISSN: None     Source Type: Journal    
DOI: 10.1002/hon.728     Document Type: Review

References (19)

1. Kakizuka A, Miller WH Jr, Umesono K, et al. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RARα with a novel putative transcription factor, PML. Cell 1991; 66: 663-673.
2. Grignani F, Ferrucci PF, Testa U, et al. The acute promyelocytic leukemia-specific PML-RARα fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell 1993; 74: 423-431.
3. Douer D. New advances in the treatment of acute promyelocytic leukemia. Int J Hematol 2002; 76(Suppl. 2): 179-187.
4. Mandelli F, Avvisati G, Lo Coco F. Advances in the understanding and management of acute promyelocytic leukemia. Rev Clin Exp Hematol 2002; 6: 60-71.
5. Davison K, Mann KK, Miller WH Jr. Arsenic trioxide: mechanisms of action. Semin Hematol 2002; 39(2 Suppl. 1); 3-7.
6. Dombret H, Fenaux P, Soignet SL, Tallman MS. Established practice in the treatment of patients with acute promyleocytic leukemia and the introduction of arsenic trioxide as a novel therapy. Semin Hematol 2002; 39(2 Suppl. 1): 8-13.
7. Mayorga J, Richardson-Hardin C, Dicke KA. Arsenic trioxide as effective therapy for relapsed acute promyelocytic leukemia. Clin J Oncol Nurse 2002; 6: 341-346.
8. Gianni M, Koken MH, Chelbi-Alix MK, et al. Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells. Blood 1998; 91: 4300-4310.
9. Lallemand-Breitenbach V, Guillemin MC, Janin A, et al. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J Exp Med 1999; 189: 1043-1052.
10. 3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins. Proc Natl Acad Sci USA 2000; 97: 10173-10178.
11. Galimberti S, Papineschi F, Carmignani A, Testi R, Fazzi R, Petrini M. Arsenic and all-trans retinoic acid as induction therapy before autograft in a case of relapsed resistant secondary acute promyelocytic leukemia. Bone Marrow Transplant 1999; 24: 345-348.
12. Grigg A, Kimber R, Szer J. Prolonged molecular remission after arsenic trioxide and all-trans retinoic acid for acute promyelocytic leukemia relapsed after allogeneic stem cell transplantation. Leukemia 2003; 17: 1916-1917.
13. Au WY, Chim CS, Lie AK, Liang R, Kwong YL. Combined arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia recurring from previous relapses successfully treated using arsenic trioxide. Br J Haematol 2002; 117: 130-132.
14. Raffoux E, Rousselot P, Poupon J, et al. Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia. J Clin Oncol 2003; 21: 2326-2334.
15. Tsimberidou AM, Estey E, Whitman GJ, et al. Extramedullary relapse in a patient with acute promyelocytic leukemia: successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies. Leuk Res 2004; 28: 991-994.
16. 3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA 2004; 101: 5328-5335.
17. Sun HD, Ma L, Hu XC, Zhang TD. Ai-Lin treated 32 cases of acute promyelocytic leukemia. Chin J Integrated Chinese Western Med 1992; 12: 170-171 (in Chinese).
18. 3 induces NB4 cell apoptosis with down-regulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 1996; 88: 1052-1061.
19. Chen GQ, Shen ZX, Wu F, et al. Pharmacokinetics and efficacy of low-dose all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Leukemia 1996; 10: 825-828.